Common variable immunodeficiency

Jonathan S. Tam, M.D., and John M. Routes, M.D.

ABSTRACT

Common variable immunodeficiency (CVID) is a common primary immunodeficiency characterized by a failure in B-cell differentiation with defective immunoglobulin production. Affected patients are uniquely susceptible to recurrent infection with encapsulated organisms and have an increased propensity for the development of inflammatory and autoimmune manifestations. The diagnosis of CVID is commonly delayed and the underlying cause of the disorder is not understood. Replacement antibody therapy reduces the risk of serious infections. However, optimal treatment regimens for the uncommon manifestations associated with this disease, such as granulomatous lymphocytic interstitial lung disease, require further research.

(Common J Rhinol Allergy 27, 260–265, 2013; doi: 10.2500/ajra.2013.27.3899)

Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by recurrent bacterial infections and impaired B-cell differentiation leading to defective immunoglobulin production. CVID is the most common clinically significant primary immunodeficiency disease. It is not a single disease, but rather a clinical syndrome that represents a family of disorders exhibiting a common phenotype. The age of onset of CVID is variable, presenting in both children and adults. The diagnosis is generally made between 20 and 40 years of age, but up to 20% may present before the age of 20 years.1 Depending on the ethnicity of the population, it affects an estimated 1 in 25,000–50,000 subjects.2–4 The true incidence of CVID may be much higher because the disease is largely underappreciated and underdiagnosed, which is reflected in the common delay in diagnosis of up to 5–10 years.1,2,5–8

PRESENTATION

Nearly all patients present with recurrent upper and/or lower respiratory tract infections including bronchitis, sinusitis, otitis media, and pneumonia. Encapsulated bacteria (Haemophilus influenzae and Streptococcus pneumoniae) are the most commonly discovered pathogens.6,8–10 In addition, patients with CVID appear to be particularly susceptible to infections with atypical bacteria such as Mycoplasma sp. and Ureaplasma sp.5,8–11 Therefore, when deciding on empiric antimicrobial therapy of respiratory tract infections, agents such as macrolides or fluoroquinolones should be considered because they cover both encapsulated and atypical organisms. Pulmonary infections with Gram-negative rods should also be considered, in particular in patients with impaired cellular immunity or longstanding CVID. Opportunistic infections are rare and occur in <10% of patients.1,8–12

Unlike congenital forms of agammaglobulinemia, such as X-linked agammaglobulinemia, T-cell abnormalities are common in patients with CVID and contribute to the more variable clinical manifestations of this disease.1,8,12 A subgroup of CVID patients termed late-onset combined immune deficiency is defined by opportunistic infections and/or severe T-cell lymphopenia (CD4 < 200 cells/mm³).13 This subgroup of patients is also more likely to have a severe clinical phenotype (gastrointestinal disease, granulomatous disease, splenomegaly, and lymphomas).

Gastrointestinal tract infections with pathogens similar to those found in X-linked agammaglobulinemia (Campylobacter jejuni, Salmonella sp, and Giardia lamblia) are also common.1 The prevalence of hepatitis C is also increased in CVID, occurring in ~12% of patients. The prognosis due to hepatitis secondary to infection with hepatitis C is poor and may be rapidly progressive in patients with CVID.14,15 Other forms of liver disease such as nodular regenerative hyperplasia are an increasingly recognized complication of CVID.1

ETIOLOGY

The etiology of the vast majority of cases of CVID is unknown. In a small subset of patients, however, specific molecular defects have been identified. Most of these genetic abnormalities are rare with the exception of mutations in TNFRSF13B, which encodes for transmembrane activator and calcium modulator and cyclophilin ligand (TACI). Mutations in TACI occur in ~8–10% of patients with CVID.16,17 Patients with heterozygous mutation in TACI are at high risk to develop CVID, whereas homozygous mutations of TACI always result in CVID.18 Patients with mutations in TACI are also more likely to have both autoimmune disease and splenomegaly.19–21

Other genetic defects leading to a CVID phenotype include mutations in inducible T-cell costimulator (ICOS), CD19, CD81, CD20, CD21, and B-cell activating factor of the tumor necrosis factor family receptor (BAFF-R).16,17,22–24 Some of these genetic mutations are likely to be disease causing (ICOS, CD19, CD20, and CD81) and others (BAFF-R) may require additional genetic contributions to lead to the CVID phenotype.12 Collectively, mutations in ICOS, CD19, CD81, CD20, CD21, BAFF-R, and TACI account for ~10–15% of all cases of CVID.

COMPLICATIONS

Acute and chronic infections are a major cause of morbidity in patients with CVID.1,7,12 The occurrence of recurrent upper respiratory tract infections can result in chronic sinusitis and hearing loss. Recurrent lower respiratory tract infections (i.e., pneumonia) may lead to the development of bronchiectasis (Fig. 1), which is reported to be present in up to 20% of patients with CVID.29,30 In addition to infectious complications in the lung parenchymal and interstitial changes may be found leading to both obstructive and restrictive defects (Table 1).

Of particular concern, is a restrictive interstitial lung disease, which on biopsy reveals granulomatous and lymphoproliferative histopathologic patterns (lymphocytic interstitial pneumonitis, follicular bronchiolitis, and lymphoid hyperplasia). The term granulomatous and lymphocytic lung disease (granulomatous lymphocytic interstitial lung disease [GLILD]) has been used to characterize this disorder and occurs in ~10–25% of patients with CVID.29–35 Progressive pulmonary impairment due to GLILD appears to be an important cause of morbidity and mortality in CVID and shows a shortened median survival (13.7 years versus 28.8 years in those without this...
complication). This noncaseating granulomatous disease is systemic in nature and may be present in the lung, bone marrow, liver, and lymph nodes. Consequently, this disease process is often confused with sarcoidosis; but unlike sarcoid, these lesions do not remit spontaneously or resolve with steroid administration. In addition to granuloma, polyclonal lymphocytic infiltration or nonmalignant hyperplasia of the lymph nodes (cervical, mediastinal, and abdominal lymph nodes as well as the spleen) are found in at least 20% of CVID subjects. Lymphoid infiltrates can occur in the lungs or other organs such as the liver and kidneys. Enlarged lymph nodes usually show atypical or reactive hyperplasia, with or without preservation of germinal center boundaries.

Patients with CVID are also at high risk to develop malignancy, which occurs in up to 15% of patients. In particular, the prevalence of non-Hodgkin’s lymphomas and gastric carcinoma is increased in CVID and are a major cause of morbidity and mortality. When lymphomas appear in CVID, they are usually extranodal, B cell in origin, negative for Epstein-Barr virus, and are more common in subjects in the 4th to 7th decades of life. Interestingly, although patients with CVID are unable to make antibodies to foreign antigens, they show a propensity to make autoantibodies; the overall prevalence of autoimmune disease is 20–25%. They are susceptible to a wide range of autoimmune diseases, but autoimmune thrombocytopenia and autoimmune hemolytic anemia are the most commonly reported cytopenias occurring in 11–12% of subjects.

The most common gastrointestinal manifestation of CVID is transient or persistent diarrhea, found in 21–57% of patients. In addition to bacterial and parasitic infections, chronic gastritis and inflammatory bowel disease are significant problems for patients with CVID. Small bowel enteropathy in CVID resembles celiac disease with short villi, crypt hyperplasia, and intraepithelial lymphocytosis. This small bowel enteropathy can lead to diarrhea, weight loss, and malabsorption. Large bowel enteropathy resembling Crohn’s disease and ulcerative colitis has also been described in CVID, although it is not clear if these have the same pathogenesis as classic inflammatory bowel disease. Furthermore, a subset of individuals (8% in one cohort) with CVID exhibit nodular lymphoid hyperplasia on biopsy—most commonly presenting as cholestasis or portal hypertension.

Based on the European Society for Immunodeficiency CVID registry and recently reproduced in additional cohorts, efforts have been made to divide patients into five distinct phenotypes based on intrinsic disease-related complications: no complications, autoimmunity, polyclonal lymphocytic infiltration, enteropathy, and lymphoid malignancy. The outcome of individual patients appears to be dependent on the presence or absence of some of these specific complications. These phenotypes are not exclusive because the lymphoproliferative phenotype (GLILD, splenomegaly, and adenopathy) is frequently accompanied by autoimmune cytopenias, gastrointestinal, and hepatic disease. As treatments for infection have improved, complications such chronic lung disease, malignancy, and autoimmune disease are now the most common causes of mortality in CVID. In a recent analysis of 411 subjects with CVID in which 19% had died, the
predominant causes of death included respiratory failure from chronic lung disease, lymphoid or other malignancy, and liver disease. Interestingly, not all complications were shown to be associated with reduced mortality. Risk factors for early mortality included gastrointestinal disease, liver disease, chronic lung disease, and lymphoma whereas autoimmune and cancer other than lymphoma were not associated with early mortality.

**DIAGNOSTIC EVALUATION**

The diagnostic criteria for CVID include:

- Decreased serum IgG level, AND decreased serum IgA or IgM
- Decreased ability to make specific antibodies in response to immunizations
- Exclusion of primary immunodeficiencies leading to decreased IgG
- Exclusion of secondary causes of decreased serum IgG
- Greater than 2 years of age

In patients with CVID, IgG levels are reduced by >2 standard deviations from the mean in all patients and <450 mg/dL in 94.2% of patients at diagnosis.2 Almost all cases of CVID have a decrease in IgA (usually <5 mg/dL) and reductions in IgM in about one-half of cases.1,2,5,6,52 Specific antibody responses, which are impaired in CVID, are shown by measuring specific antibodies 3–4 weeks after the administration of a protein (i.e., tetanus, diphtheria toxoid, *H. influenzae* B) and polysaccharide (pneumococcal vaccine) vaccines.53 Early in life CVID is not always discernible from transient hypogammaglobulinemia of infancy or congenital forms of agammaglobulinemia. Therefore, the general consensus is that this diagnosis of CVID should not be made until after a patient reaches the age of 2 years.12

Exclusion of other secondary causes of hypogammaglobulinemia is especially important in patients with isolated low IgG (Table 2).1,2,12,54–56 Protein loss from protein losing enteropathy or nephrotic syndrome can present as hypogammaglobulinemia and is not uncommon. Chronic oral corticosteroid use can also lead to reduced IgG levels and is a common cause of hypogammaglobulinemia in patients with severe asthma or chronic obstruction pulmonary disease. The decrease in serum IgG occurs is relatively selective with a relative sparing of the IgA and IgM and normal specific antibody disease. The decrease in serum IgG after corticosteroid therapy is dependent on the dose and duration of steroid therapy. Although corticosteroid therapy typically does not reduce serum IgG to <400 mg/dL, reduction below this level may be seen in patients receiving high doses of corticosteroids over a long period of time.57,58 Other common medications associated with hypogammaglobulinemia include rituximab, azathioprine, sulfasalazine, and several anticonvulsants (carbamazepine, levetiracetam, oxcarbazepine, and phenytoin).59–63

The physical examination of a patient with a suspected CVID requires an in-depth focus on the involved organ systems. The chest examination often may reveal wheezing, ronchi, or cracks in patients with CVID-associated lung disease. The clinician should observe specifically for clubbing or cyanosis and use of accessory muscles for respiration. Careful periodic examination of the lymph nodes (cervical, axillary, or inguinal) and spleen is important, because patients with CVID also frequently have adenopathy and splenomegaly, which can be quite profound.

Laboratory evaluation would include quantitative immunoglobulins (IgG, IgA, and IgM) and functional antibody testing. Flow cytometry should enumerate the total numbers of T cells, T-cell subsets (CD4 and CD8), B cells, B-cell subsets, and NK cells. B-cell subset analysis should include the percentage of total memory B cells, switched memory B cells, and CD21(lo) B cells.64–67

B-cell numbers are variable in CVID, and if reduced may indicate a poorer prognosis.1,4 Low numbers of switched memory B cells (CD27+IgM–IgD–) in the peripheral blood are frequently found in patients with a more severe phenotype of CVID (e.g., GLILD)31,68 and may portend a worse prognosis. T-cell abnormalities occur in ~40% of patients and include anergy, T-cell lymphopenia, and poor proliferative responses to mitogens and antigens.

**TREATMENT**

The primary treatment of CVID is antibody replacement with either i.v. or subcutaneous immunoglobulin with an initial dose of 400–600 mg/kg of gammaglobulin per month.2,70 This dose can be divided every 3–4 weeks for i.v. administration or every 1–2 weeks for subcutaneous administration. Both i.v. and subcutaneous methods have been shown to be safe and effective for replacement.12,70–73

Subsequent dosing should not be based on IgG immunoglobulin level, but rather on preventing infection. Although trough IgG levels should be drawn before initial administration and may be used to help guide therapy, recent studies have shown that individualized dose adjustments based on clinical course may be preferable to blanket goal IgG trough levels.74,75 Furthermore, higher doses are required for patients with significant pulmonary disease (i.e., bronchiectasis), sinus disease, GLILD, or splenomegaly.73 Once patients are established on immunoglobulin replacement therapy, IgG trough levels are measured every 6–12 months to ensure adequate dosing with a minimum trough level of 400 mg/dL.

There is no convincing evidence that one brand of gammaglobulin is better than others in reducing infections. However, products do differ in their preparation, and when choosing a product one must consider osmolarity, pH, sodium, sugar, and IgA content. A full
Additives in the preparations used to prevent protein aggregation—such as amino acids, sorbitol, salt, or sucrose—may lead to adverse effects in certain clinical settings. For example, sugar content should be considered in a patient with diabetes or prediabetes. Furthermore, sucrose content has been associated with renal failure or insufficiency. Because of the large protein load, patients with renal dysfunction might want to avoid intravenous immunoglobulin (IV Ig) entirely, using subcutaneous immunoglobulin instead. The major contributors to osmolality in IV Ig are sodium and sugar content. Reconstitution of lyophilized preparations can also result in hypertonic osmolar solutions. Osmolality is an important concern because hypotonic states have been implicated in thrombotic complications.

Although the mortality of CVID caused by common infectious pathogens has declined with the increased use of high-dose immunoglobulin replacement, patients may continue to develop obstructive, restrictive, or bronchiectatic changes. In fact, GLILD is refractory to gammaglobulin replacement therapy and bronchiectasis may develop despite antibody replacement therapy.

For the most part, many of the complications of CVID may be treated in the same manner as immunocompetent patients with similar diseases. Oral corticosteroids, immunomodulatory dosages of IV Ig (2 g/kg per month), and rituximab have been used to treat autoimmune hemolytic anemia or autoimmune thrombocytopenia in patients with CVID. Splenectomy is to be avoided, because severe infections have occurred. Treatment of bronchiectasis in patients with CVID is similar to the therapy of idiopathic bronchiectasis. Mobilization of pulmonary secretions through the use of medications such as β2-agonists along with chest physiotherapy is frequently used, although there are few trials that show the effectiveness of pulmonary hygiene.

The optimal treatment for GLILD in CVID is unknown, but these patients appear to have a high mortality rate if left untreated. GLILD is resistant to corticosteroid therapy so alternative treatment regimens should be considered. Steroid sparing agents such as azathioprine, 6-mercaptopurine, cyclosporine A, mycophenolate mofetil, or methotrexate have been tried with inconsistent results. TNF inhibitors have also been tried and some success has been reported. However, the low prevalence of this complication in CVID patients makes controlled or open trials difficult. Recent data from a retrospective analysis of seven CVID patients with biopsy-proven GLILD aged 18–43 years suggests that combination chemotherapy with rituximab and azathioprine may be beneficial in this select patient population. Patients showed statistically significant improvement in HRCT score (p < 0.011) and pulmonary function testing (forced expiratory volume in 1 second, p < 0.04 and forced vital capacity, p < 0.036). These findings are encouraging but highlight the urgent need for similar prospective studies to ascertain the most effective medications, optimal timing, duration of therapy, and effect on long-term morbidity and mortality.

**CONCLUSION**

CVID is a complex, multifocal disease with a large array of clinical manifestations and complications. Treatment with gammaglobulin and improved antibiotic coverage have vastly improved the outlook for patients; however, as infections and infectious complications become less prominent, morbidities from disordered inflammation or immune dysregulation have become greater areas of concern. Continued studies are needed to illuminate the many causes of this disease and possibly therapeutic targets.

**REFERENCES**

1. Resnick ES, Mosher EL, Godbold JH, and Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 119:1650–1657, 2012.
2. Chapell H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112:277–286, 2008.
3. Stray-Pedersen A, Abrahamsen TG, and Froland SS. Primary immune deficiency diseases in Norway. J Clin Immunol 20:477–485, 2000.
4. Fasth A. Primary immunodeficiency disorders in Sweden: Cases among children, 1974–1979. J Clin Immunol 2:86–92, 1982.
5. Urschel S, Kayikci L, Wintergerst U, et al. Common variable immune deficiency disorders in children: Delayed diagnosis despite typical clinical presentation. J Pediatr 154:888894, 2009.
6. Okenhendler E, Gerard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 46:1547–1554, 2008.
7. Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 27:308–316, 2007.
8. Cunningham-Rundles C, and Bodian C. Common variable immunodeficiency: Clinical and immunological features of 248 patients. Clin Immunol 92:34–48, 1999.
9. Gelfand EW. Unique susceptibility of patients with antibody deficiency to mycoplasma infection. Clin Infect Dis 17(suppl 1):S520–S523, 1993.
10. Rooban CM, Rao CP, Lederman HM, et al. Increased susceptibility to mycoplasma infection in patients with hypogammaglobulinemia. Am J Med 80:590–594, 1986.
11. Hermaszewski RA, and Webster AD. Primary hypogammaglobulinemia: A survey of clinical manifestations and complications. Q J Med 86:31–42, 1993.
12. Yong PFK, Thaventhiran JED, and Grimbacher B. A rose is a rose, but CVID is not CVID. Common variable immune deficiency (CVID), what do we know in 2011? In Advances in Immunology, Chap. 2. Frederick WA (Ed). Waltham, MA: Academic Press, 47–107, 2011.
13. Malphettes M, Gérard L, Carmagnat M, et al. Late-onset combined immune deficiency: A subset of common variable deficiency with severe T cell defect. Clin Infect Dis 49:1329–1338, 2009.
14. Ermis F, Akızyüz F, Demir K, et al. Rapidly progressive HCV cirrhosis in a hypogammaglobulinemic patient. Intern Med 47:415–417, 2008.
15. Fellermann K, and Stange EF. Chronic hepatitis C, common variable immunodeficiency and autoimmune hemolytic anemia. Coincidence by chance or common etiology? Hepatogastroenterology 47:1422–1424, 2000.
16. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37:829–834, 2005.
17. Castiglì E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37:829–834, 2005.
18. Salzer U, Bacchelli C, Buckridge S, et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 113:1967–1976, 2009.
19. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 28(suppl 1):S42–S45, 2008.
24. Castigli E, and Geha RS. TACI, isotype switching, CVID and IgAD. Clin Immunol Rev 36:102–111, 2007.
25. Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201:35–39, 2005.
26. Salzer U, Maut-Pavic A, Cunningham-Rundles C, et al. ICOS deficiency in patients with common variable immunodeficiency. Clin Immunol 113:234–240, 2004.
27. Grimbacher B, Hultoff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 4:261–268, 2003.
28. Orange JS, Glessner JT, Resnick E, et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol 127:1360–1367, 2011.
29. Busse PJ, Farzan S, and Cunningham-Rundles C. Pulmonary complications of common variable immunodeficiency. Ann Allergy Asthma Immunol 98:1–8, 2007.
30. Bates CA, Ellison MC, Lynch DA, et al. Granulomatous-lymphocytic interstitial lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 114:415–421, 2004.
31. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: Defining subgroups in common variable immunodeficiency. Blood 111:77–85, 2008.
32. Arnold DF, Wiggins J, Cunningham-Rundles C, et al. Granulomatous disease: Distinguishing primary antibody disease from sarcoidosis. Clin Immunol 128:18–22, 2008.
33. Buckley RH. Pulmonary complications of primary immunodeficiencies. Paediatr Respir Rev 5(suppl A):S225–S233, 2004.
34. Mechanic LJ, Dikman S, and Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 127:63–4, 1997.
35. Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy 60:203–206, 1988.
36. Morimoto Y, and Routes JM. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep 5:370–375, 2005.
37. Sander CA, Medeiro LS, Weiss LM, et al. Lymphoproliferative lesions in patients with common variable immunodeficiency syndrome. Am J Surg Pathol 16:1170–1182, 1992.
38. Cunningham-Rundles C, Lieberman P, Hellman G, and Chaganti RS. Non-Hodgkin lymphoma in common variable immunodeficiency. Am J Hematol 37:69–74, 1991.
39. Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 33:30–39, 2013.
40. Salavourea K, Koliali A, Tsangaris G, and Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 28:1263–1269, 2008.
41. Mellemkjaer L, Hammarstorm L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: A combined Danish and Swedish study. Clin Exp Immunol 126:495–500, 2002.
42. Kirken LJ, Webster AD, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet 1:263–266, 1985.
43. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, and Lieberman P. Incidence of cancer in 98 patients with common variable immunodeficiency. J Clin Immunol 7:294–299, 1987.
44. Agarwal S, and Cunningham-Rundles C. Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 9:347–352, 2009.
45. Lopes-da-Silva S, and Rizzo LV. Autoimmunity in common variable immunodeficiency. J Clin Immunol 28(suppl 1):S46–S55, 2008.
46. Washington K, Stenzel TT, Buckley RH, and Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol 20:1240–1252, 1996.
47. Daniels JA, Lederman HM, Maitra A, and Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): A clinicopathologic study and review. Am J Surg Pathol 31:1800–1812, 2007.
48. Khodadad A, Aghamohammadi A, Parvaneh N, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci 52:2977–2983, 2007.
49. Chapel H, Lucas M, Patel S, et al. Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts. J Allergy Clin Immunol 130:1197–1205, 2012.
50. Park JH, and Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol 134:97–103, 2010.
51. Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: The main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol 48:74–82, 2008.
52. Notarangelo L, Day N, and Fleisher T. 2nd Conference of the Robert A. Free immunodeficiency society primary immune deficiencies and immune reconstitution Harvard Medical Boston, November 16th, 17th. Immune Res 44:1–3, 2009.
53. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 130(suppl):S1–S24, 2012.
54. Chapel H, and Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 145:709–727, 2009.
55. Lee AH, Levinson AI, and Schumacher HR Jr. Hypogammaglobulinemia and rheumatic disease. Sem Arthritis Rheum 22:252–264, 1993.
56. Hayman G, and Bansal A. Antibody deficiency associated with carboxyamine. BMJ 325:1213, 2002.
57. Azar AE, and Ballas ZK. Reversible panhypogammaglobulinemia associated with antiepileptic agent levetiracetam. Ann Allergy Asthma Immunol 101:108–109, 2008.
58. Sanchez-Ramon S, Radigan L, Yu JE, et al. Memory B cells in common variable immunodeficiency: Clinical associations and sex differences. Clin Immunol 128:314–321, 2008.
59. Ko J, Radigan L, Yu JE, et al. Memory B cells in common variable immunodeficiency. Clin Immunol 128:314–321, 2008.
60. Sanchez-Ramon S, Radigan L, Yu JE, et al. Memory B cells in common variable immunodeficiency: Clinical associations and sex differences. Clin Immunol 128:314–321, 2008.
61. Piqueiras B, Lavenue-Bomblec C, Galier C, et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J Clin Immunol 23:365–400, 2003.
62. Warnatz K, Dzen A, Drager R, et al. Severe deficiency of switched memory B cells (CD27(−)IgM(−)IgD(−)) in subgroups of patients with common variable immunodeficiency: A new approach to classify a heterogeneous disease. Blood 99:1544–1551, 2002.
63. Chase NM, Verbsky JW, Hintemeyer MK, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 33:30–39, 2013.
64. Ward C, Lucas M, Piris J, et al. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol 153:331–337, 2008.
65. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117(suppl):S552–S555, 2006.
66. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet 345:365–369, 1995.
72. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 28:779–802, 2008.
73. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20:94–100, 2000.
74. Orange JS, Grossman WJ, Navickis RJ, and Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 137:21–30, 2010.
75. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 125:1354–1360 e4, 2010.
76. Immune Deficiency Foundation. 2012. Characteristics of Immune Globulin Products Currently Licensed for Use in the United States: http://primaryimmune.org/treatment-information/immunoglobulin-products.
77. Hooper JA. Intravenous immunoglobulins: Evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 28:765–778, 2008.
78. Shelton B, Griffin J, and Goldman F. Immune globulin IV therapy: Optimizing care of patients in the oncology setting. Oncol Nurs Forum 33:911–921, 2006.
79. Hansen-Schmidt S, Silomon J, and Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 28:451–453, 1996.
80. Nydegger UE, and Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 21:171–185, 1999.
81. Busse PJ, Razvi S, and Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109:1001–1004, 2002.
82. Kim JJ, Thrasher AJ, Jones AM, et al. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency. Br J Haematol 138:94–96, 2007.
83. El-Shanawany TM, Williams PE, and Jolles S. Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. J Clin Pathol 60:715–716, 2007.
84. Mahevas M, Le Page L, Salle V, et al. Efficiency of rituximab in the treatment of autoimmune thrombocytopenic purpura associated with common variable immunodeficiency. Am J Hematol 81:645–646, 2006.
85. Seve P, Bourdillon L, Sarrot-Reynauld F, et al. Autoimmune hemolytic anemia and common variable immunodeficiency: A case-control study of 18 patients. Medicine 87:177–184, 2008.
86. Indinnimeo L, Tancredi G, Barreto M, et al. Effects of a program of hospital-supervised chest physical therapy on lung function tests in children with chronic respiratory disease: 1-Year follow-up. Int J Immunopathol Pharmacol 20:841–845, 2007.
87. Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. Chest 129(suppl):122S–131S, 2006.
88. Thatayatikom A, Thatayatikom S, and White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: A case report and review of the literature. Ann Allergy Asthma Immunol 95:293–300, 2005.
89. Hatab AZ, and Ballas ZK. Caseating granulomatous disease in common variable immunodeficiency treated with infliximab. J Allergy Clin Immunol 116:1161–1162, 2005.